J&J pharma leader to retire; Krystal slumps on gene therapy miss

Negative

AI Analysis

Summary

Jennifer Taubert to retire from her role leading J&J's pharmaceutical business. Krystal's gene therapy launch underperformed due to pricing issues despite analyst expectations for a strong launch.

Outcome Details

gene therapy launch hampered by pricing issues

Importance:4/10

Sentiment:

-0.40

management changegene therapypricing issuesproduct launch

Related Companies

$JNJ $KRYS

Read the original article

Published by BioPharma Dive on August 4, 2026 2:20 PM

Read Original